Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)

Insulin Dependent ◽

Gfr Decline ◽

Post Hoc ◽

Faculty of 1000 evaluation for Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT).

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718171154.793487536 ◽

2013 ◽

Author(s):

Enyu Imai

Keyword(s):

Diabetic Nephropathy ◽

Angiotensin Ii ◽

Kidney Failure ◽

Estimated Gfr ◽

Post Hoc Analysis ◽

Insulin Dependent ◽

Gfr Decline ◽

Post Hoc ◽

Faculty Opinions recommendation of Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725503819.793507757 ◽

2015 ◽

Author(s):

Luis Ruilope ◽

Enrique Morales

Keyword(s):

Diabetic Nephropathy ◽

Angiotensin Ii ◽

Kidney Disease ◽

Serum Bicarbonate ◽

Post Hoc Analysis ◽

Insulin Dependent ◽

Kidney Disease Progression ◽

Post Hoc ◽

Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial)

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2015.03.032 ◽

2015 ◽

Vol 66 (3) ◽

pp. 450-458 ◽

Cited By ~ 20

Author(s):

Elise Schutte ◽

Hiddo J. Lambers Heerspink ◽

Helen L. Lutgers ◽

Stephan J.L. Bakker ◽

Priya Vart ◽

...

Keyword(s):

Diabetic Nephropathy ◽

Angiotensin Ii ◽

Kidney Disease ◽

Serum Bicarbonate ◽

Post Hoc Analysis ◽

Insulin Dependent ◽

Kidney Disease Progression ◽

Post Hoc ◽

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

Journal of the American Society of Nephrology ◽

10.1681/asn.2006050445 ◽

2007 ◽

Vol 18 (5) ◽

pp. 1540-1546 ◽

Cited By ~ 206

Author(s):

Wouter B.A. Eijkelkamp ◽

Zhongxin Zhang ◽

Giuseppe Remuzzi ◽

Hans-Henrik Parving ◽

Mark E. Cooper ◽

...

Keyword(s):

Blood Pressure ◽

Diabetic Nephropathy ◽

Angiotensin Ii ◽

Post Hoc Analysis ◽

Post Hoc ◽

Type 2 Diabetic

Faculty Opinions recommendation of Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1092298.546712 ◽

2007 ◽

Author(s):

Luis Ruilope

Keyword(s):

Blood Pressure ◽

Diabetic Nephropathy ◽

Angiotensin Ii ◽

Post Hoc Analysis ◽

Post Hoc ◽

Type 2 Diabetic

Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of End Points in Noninsulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial

Hypertension ◽

10.1161/hypertensionaha.111.186064 ◽

2012 ◽

Vol 59 (1) ◽

Cited By ~ 1

Author(s):

Neeraj Dhaun ◽

David J. Webb

Keyword(s):

Diabetes Mellitus ◽

Uric Acid ◽

Angiotensin Ii ◽

Dependent Diabetes Mellitus ◽

End Points ◽

Post Hoc Analysis ◽

Renal Outcomes ◽

Post Hoc ◽

Losartan Treatment

Erratum to: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Diabetologia ◽

10.1007/s00125-011-2215-4 ◽

2011 ◽

Vol 54 (8) ◽

pp. 2209-2209

Author(s):

Y. Miao ◽

D. Dobre ◽

H. J. Lambers Heerspink ◽

B. M. Brenner ◽

M. E. Cooper ◽

...

Keyword(s):

Angiotensin Ii ◽

Serum Potassium ◽

Post Hoc Analysis ◽

Renal Outcomes ◽

Post Hoc

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Diabetologia ◽

10.1007/s00125-010-1922-6 ◽

2010 ◽

Vol 54 (1) ◽

pp. 44-50 ◽

Cited By ~ 56

Author(s):

Y. Miao ◽

D. Dobre ◽

H. J. Lambers Heerspink ◽

B. M. Brenner ◽

M. E. Cooper ◽

...

Keyword(s):

Angiotensin Ii ◽

Serum Potassium ◽

Post Hoc Analysis ◽

Renal Outcomes ◽

Post Hoc

Visit-to-Visit Variability in Blood Pressure and Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Nephropathy: A Post Hoc Analysis From the RENAAL Study and the Irbesartan Diabetic Nephropathy Trial

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2014.06.008 ◽

2014 ◽

Vol 64 (5) ◽

pp. 714-722 ◽

Cited By ~ 39

Author(s):

Ciaran J. McMullan ◽

Hiddo J. Lambers Heerspink ◽

Hans-Henrik Parving ◽

Jamie P. Dwyer ◽

John P. Forman ◽

...

Keyword(s):

Blood Pressure ◽

Type 2 Diabetes ◽

Diabetic Nephropathy ◽

Cardiovascular Outcomes ◽

Post Hoc Analysis ◽

Post Hoc ◽

Faculty Opinions recommendation of Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718509953.793498052 ◽

2014 ◽

Author(s):

Kazuomi Kario ◽

Michiaki Nagai

Keyword(s):

Blood Pressure ◽

Type 2 Diabetes ◽

Diabetic Nephropathy ◽

Cardiovascular Outcomes ◽

Post Hoc Analysis ◽

Post Hoc ◽